WASHINGTON - House and Senate conferees agreed on a compromise version of securities reform litigation and both bodies are expected to vote to approve it this week, apparently with veto-proof majorities.

The key provisions of the bill of interest to the biotech industry involve "safe harbor" protection from fraud litigation for disclosure of forward-looking financial information.